Navigation Links
Debiopharm Group and Mercury Therapeutics, Inc. Sign an Exclusive License Agreement for the Development and Commercialisation of Debio 0930
Date:8/4/2009

Located in Woburn, Massachusetts, Mercury Therapeutics is a privately held biotech company focusing on the development of AMPK activators as novel therapeutics for type 2 diabetes, cancer and cardiovascular disease. Mercury is focusing its internal AMPK drug development program for indications in oncology. Mercury's lead generation platform is based on a proprietary technology that enables the discovery and development of novel compounds that directly activate AMPK, a key regulator of whole body energy metabolism, cholesterol and fatty acid production, and cell division.

For more information on Mercury Therapeutics please visit: http://www.mtipharm.com.

    Debiopharm S.A. Contact:
    Maurice Wagner
    Director Corporate Affairs & Communication
    Tel: +41(0)21-321-01-11
    Fax: +41(0)21-321-01-69
    mwagner@debiopharm.com

    Additional Media Contacts:

    In London
    Maitland
    Brian Hudspith
    Tel: +44(0)20-7379-5151
    bhudspith@maitland.co.uk

    In New York
    Russo Partners, LLC
    Martina Schwarzkopf, Ph.D.
    Account Executive
    Tel: +1-212-845-4292
    Fax: +1-212-845-4260
    martina.schwarzkopf@russopartnersllc.com

    Mercury Therapeutics Contact:
    Neal Birnberg, CEO
    Tel: +1-781-932-1125
    Fax: +1-781-347-4737
    birnberg@mtipharm.com


'/>"/>
SOURCE The Debiopharm Group
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations
2. Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations
3. Salvacyl(R), Developed by Debiopharm, is Launched in two European Countries
4. Clinical Update - Debio 9902 SR (ZT-1) for Alzheimer Patients Debiopharm Starts Tablet Formulations Bridging Study under IND
5. Debiopharm Moves Towards a New 6-Month Formulation of Decapeptyl(R) to Further Help Prostate Cancer Patients
6. Debiopharm and EPFL Sign Research Project Agreement to Identify Inhibitors of Signalling Pathways Controlling Cell Fate for Cancer Treatment
7. Commonwealth Fund Case Study Points to Continuous Innovation at Group Health Cooperative
8. Top Medical Research Centers Form Velos Advisory Group for Service-Oriented Architecture
9. New Federal Stem Cell Rules Would Hinder Existing Research, Consumer Group Warns
10. Encorium Group Provides Update to LOI with Respect to the Sale of its U.S. Business
11. The Villa Group Informs on Mexico Travel Plans in Wake of Swine Flu Outbreak
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... , Dec. 15, 2014  Colorado and ... have legalized adult use of cannabis. Oregon ... D.C. ended prohibition during the November 2014 elections. ... Photo - http://photos.prnewswire.com/prnh/20141212/164153LOGO The benefits ... noted and obvious benefits like the increased tax revenue for ...
(Date:12/15/2014)... 2014   DaVita HealthCare Partners Inc.  (NYSE: ... largest and most innovative health care communities, today ... DaVita Clinical Research  (DCR) and  HealthCare Partners Clinical Research ... extensive clinical research and data analytics services, specifically ... end-stage renal disease (ESRD), as well as primary ...
(Date:12/13/2014)... 11, 2014 Research and Markets ... the "Drug Injection Devices to 2020" ... http://photos.prnewswire.com/prnh/20130307/600769 As new drugs ... list of health conditions, drug developers have increasingly ... administration process and increase the efficiency and reliability ...
Breaking Medicine Technology:CannaInsider.com Estimates 200,000 New Jobs in the Cannabis Industry by 2015 2DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 2DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 3DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 4Drug Injection Devices to 2020 2Drug Injection Devices to 2020 3Drug Injection Devices to 2020 4
... ( US HIFU ), a world leader in minimally invasive ... ) technologies and manufacturer of the Sonablate® 500 medical device ... available to prostate cancer patients for the first ... Curitiba, capital city of the state of Parana in southern ...
... Medical, Inc. ("Kips Bay"), a development stage medical device ... vein support technology, or eSVS MESH, for use in ... it has closed its previously announced offering of 2,062,500 ... $8.00 per share.   Kips Bay ...
Cached Medicine Technology:Sonablate® HIFU for Prostate Cancer in New Locations Outside the U.S. 2Sonablate® HIFU for Prostate Cancer in New Locations Outside the U.S. 3Sonablate® HIFU for Prostate Cancer in New Locations Outside the U.S. 4Kips Bay Medical Announces Closing of its $16.5 Million Initial Public Offering of Common Stock 2
(Date:12/17/2014)... gas prices rose in recent years, so did motorcyclist ... times of gas increases, more people start using motorcycles ... explained. They examined data gathered between 2002 and ... motorcycle registrations in the United States and the third ... a strong association between rising gas prices and an ...
(Date:12/17/2014)... HealthDay Reporter TUESDAY, Dec. 16, 2014 ... a new study reveals that states that routinely perform randomized ... on their roads. The finding suggests that states that ... deter inebriated revelers from getting behind the wheel in the ... regarding drinking and driving," said study lead author James Fell, ...
(Date:12/15/2014)... CITY, NV (PRWEB) December 15, 2014 ... powerhouse company, JM Ocean Avenue. JM Ocean Avenue ... of the Veretekk online automated marketing system. JM ... the June 2014 merger of Ocean Avenue and JM ... more than $2 Billion per year company. , “After ...
(Date:12/15/2014)... 15, 2014 Health Dialog, a ... today that it has received Patient Oriented Accreditation ... for its Disease Management (DM) Programs for asthma, ... coronary heart disease and diabetes. This marks the ... Health Dialog’s Disease Management (DM) Programs, reaffirming Health ...
(Date:12/15/2014)... Austin, TX (PRWEB) December 15, 2014 ... with offices in 26 countries in North and South ... begun accepting responses from industry participants for its 2015 ... survey in order to identify upcoming business and market ... industry respondents. , The survey targets areas including:, ...
Breaking Medicine News(10 mins):Health News:When Gas Prices Go Up, So Do Motorcycle Accidents, Study Finds 2Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 2Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 2Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 4Health News:Health Dialog Receives NCQA Accreditation for Disease Management Programs 2Health News:Emergo’s Annual Survey Assessing the State of the Medical Device Industry Now Open 2
... pain caused by osteoarthritis , , THURSDAY, Nov. 8 (HealthDay News) ... sufferers, a preliminary study found. , "We don,t recommend people ... study author Dr. Jasvinder Singh, a staff physician at the ... and more patients needed to be assessed before the treatment ...
... have discovered that a molecular switch in the protein making ... common forms of lethal breast cancer worldwide. The discovery by ... therapies for the cancer, called locally advanced breast cancer (LABC)., ... LABC may account for 50 percent or more of breast ...
... in annual ,America,s Best,Health Plans, issue, ATLANTA, Nov. 8 ... placed Kaiser Permanente of Georgia first in,the state for the ... The magazine, on newsstands Nov. 5, 2007, also ranked Kaiser,Permanente,s ... the top,Medicare plan in the state for 2007 and one ...
... WEST BRIDGEWATER, Mass., Nov. 8 Pressure,BioSciences, Inc. (Nasdaq: ... host,a teleconference to discuss its third quarter financial results ... to the,teleconference either by telephone or through a live ... Date: Monday, November 12, 2007 Time: 4:30 p.m. ...
... Matthew Gregory, the Washington,state man who,s spent more than ... Research Center, expects to conclude his odyssey,today at the southernmost ... Sept. 1, 2006, Gregory set out from his home near ... and quit his job,with a beverage distributor to accommodate his ...
... a business integration,provider focused exclusively on health ... has purchased HealthASPex (HAX) through an,asset sale. ... PPO routing,services to Third Party Administrators (TPAs) ... http://www.newscom.com/cgi-bin/prnh/20050113/SFTH042LOGO ) "Tela,s streamlined front-end service ...
Cached Medicine News:Health News:Botox Offers Shot in Arm for Arthritis Sufferers 2Health News:A molecular switch is linked to a common breast cancer 2Health News:U.S. News & World Report Names Kaiser Permanente Top-Ranked Health Plan in Georgia 2Health News:Pressure BioSciences, Inc. to Discuss Third Quarter Financial Results and Provide Business Update 2Health News:Cross-Country Walker to Finish His Journey for Cancer Research 2Health News:Tela Sourcing, Inc., an Adaptis Company, Acquires HealthASPex Business 2
This cannula is flanged with radiopaque tip with 2 side holes....
This cannula features a PVC body, auto inflatable smooth cuff, pressure monitoring line with integral stopcock....
The KAVD Venous Cannula is the first of its kind. It is a combination of cannulae/venous line designed to "bridge the gap between the patient and the Medtronic Resting Heart System circuit....
The DLP Elongated One-Piece Arterial Cannulae features a longer body for easier access during conventional and minimally invasive procedures...
Medicine Products: